ClinicalTrials.gg
CompletedNCT03525626Updated Jul 9, 2019

Online Mindfulness-based Tic Reduction

An interventional study of Online Mindfulness-based Tic Reduction in Tourette Syndrome and Tic Disorders, sponsored by Bowdoin College. Completed at 2 sites in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2019-07-09.

Sponsored by Bowdoin College · Not applicable, Interventional, and Other

Phase
Not applicable
Study type
Interventional
Enrollment
6
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Study summary

Tourette Syndrome (TS) and Persistent Tic Disorder (PTD) are chronic and potentially disabling neurobiological conditions. Although a range of pharmacological and psychosocial treatments exists, a significant number of individuals either do not respond to the current treatments, find them unacceptable, or cannot access them. Thus, it is essential that researchers continue to pursue novel treatment approaches that can also be easily disseminated to those in need.

Initial pilot data suggest that a mindfulness-based intervention may be beneficial for adults with tic disorders. In the present study, the researchers aim to further develop this mindfulness-based intervention, adapt it to be delivered online and pilot test the intervention with a small group of participants. The data from this pilot test will inform a subsequent randomized controlled trial comparing online mindfulness-based tic reduction to online psychoeducation, relaxation, and supportive therapy.

The specific aim is to determine the feasibility and acceptability of Online Mindfulness-based Tic Reduction in 6 adults with TS or PTD.

The researchers hypothesize that Online Mindfulness-based Tic Reduction will be feasible and acceptable to adults with tic disorders as measured by participant satisfaction, qualitative participant feedback, home practice compliance, dropout, and adverse events.

02

Conditions studied

  • Tourette Syndrome
  • Tic Disorders

Keywords

  • Tic Disorders
  • Mindfulness
  • Meditation
  • Online
  • Internet-based
  • Treatment
03

In context

Tourette Syndrome

240 studies on the registry are indexed under Tourette Syndrome; 40 are open to participants now.

This study's enrollment of 6 is below the median of 36 across 183 interventional studies indexed under Tourette Syndrome.

Browse Tourette Syndrome studies →

Lead sponsor

Bowdoin College is the lead sponsor of 3 studies on the registry; none are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. 18 years of age or older,
  2. possess a primary diagnosis of Tourette Syndrome or Persistent Tic Disorder,
  3. fluent in English
  4. residing in the United States,
  5. either not be taking any tic suppressant medication or other psychotropic medication or be at a stable dose for 8 weeks prior to the baseline assessment and throughout the study

Exclusion criteria

Exclusion Criteria:

  1. be receiving concurrent psychotherapy for the duration of the study
  2. have prior extensive experience with mindfulness and/or meditation and
  3. cannot have another medical or psychological condition that would prevent the individual from fully engaging in the study or require a higher level of care (e.g., suicidality).
05

Study design

Phase
Not applicable
Primary purpose
Other
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
6 participants (actual)

Study arms

  • Experimental
    Online Mindfulness-based Tic Reduction

    Behavioral: Online Mindfulness-based Tic Reduction

Interventions

  • BehavioralOnline Mindfulness-based Tic Reduction

    8-week online group mindfulness-based intervention for tics

06

What researchers measure

Primary outcomes

  1. Patient Satisfaction Questionnaire

    Time frame: week 9

Secondary outcomes

  1. Homework Compliance Questionnaire

    Time frame: Weeks 1-8

  2. Attrition Form

    Time frame: Weeks 1-8

  3. Adverse Events Monitoring Form

    Time frame: Weeks 1-9

  4. Yale Global Tic Severity Scale (YGTSS)

    Time frame: Week 0, Week 9

  5. Adult Tic Questionnaire

    Time frame: Weeks 0-9

  6. Clinical Global Impressions Scale-Severity

    Time frame: Week 0, Week 9

  7. Clinical Global Impressions Scale-Improvement

    Time frame: Week 9

Other outcomes

  1. Yale-Brown Obsessive Compulsive Scale

    Time frame: Week 0, Week 9

  2. Attention Deficit Hyperactivity Disorder Rating Scale

    Time frame: Week 0, Week 9

  3. Patient Health Questionnaire-9

    Time frame: Week 0, Week 9

  4. Work and Social Adjustment Survey

    Time frame: Week 0, Week 9

  5. Five Facet Mindfulness Questionnaire

    Time frame: Weeks 0-9

  6. Credibility and Expectancy Questionnaire

    Time frame: Week 3

  7. Self Compassion Scale

    Time frame: Week 0, Week 9

  8. Affective Reactivity Index

    Time frame: Week 0, Week 9

  9. Brief Irritability Test

    Time frame: Week 0, Week 9

07

Study locations

2 sites
  • Bowdoin College
    Brunswick, Maine 04011, United States
  • Massachusetts General Hospital
    Boston, Massachusetts 02114, United States
08

References and documents

Publications

  • Reese HE, Brown WA, Summers BJ, Shin J, Wheeler G, Wilhelm S. Feasibility and acceptability of an online mindfulness-based group intervention for adults with tic disorders. Pilot Feasibility Stud. 2021 Mar 24;7(1):82. doi: 10.1186/s40814-021-00818-y. PubMed 33757602 ↗
09

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Jul 9, 2019, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT03525626
Lead sponsor
Bowdoin College
Responsible party
Hannah Reese (Assistant Professor, Bowdoin College) — Principal investigator
First posted
May 15, 2018
Start date
Apr 4, 2018
Primary completion
Aug 7, 2018
Completion
Aug 7, 2018
Last update
Jul 9, 2019

Study contacts

Hannah Reese, Ph.D.
principal investigator · Bowdoin College

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jul 2019. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion